You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy - 2022
Completed
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +4 more
  • Eltrombopag Olamine
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-04
Jan 4, 2022
N
Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia
Recruiting
  • Validity and Safety
    • Guangzhou, Guangdong, China
      NanfangH
    2021-09-02
    Sep 2, 2021
    H
    Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    Active, not recruiting
    • Chronic Myelogenous Leukemia
    • Amman, Jordan
    • +4 more
    2022-01-17
    Jan 17, 2022
    A
    A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia - 2021
    Terminated
    Has Results
    • Chronic Phase Chronic Myeloid Leukemia
    • Ponatinib 30 mg QD
    • +2 more
    • Bruxelles, Belgium
      Cliniques Universitaire Saint-Luc (Site 058)
    2021-10-28
    Oct 28, 2021
    T
    A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia
    Recruiting
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Chronic Phase Chronic Myelogenous Leukemia
    • Text Message-Based Navigation Intervention
    • Survey Administration
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    2022-04-07
    Apr 7, 2022
    C
    A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - 2019
    Completed
    • Chronic Myelogenous Leukemia - Chronic Phase
    • Dasatinib Tablets
    • Shenzhen, Guangdong, China
    • +3 more
    2021-06-11
    Jun 11, 2021
    M
    Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment - 2021
    Completed
    • Chronic Myelogenous Leukemia, BCR-ABL Positive
    • CML, Chronic Phase
    • Pioglitazone 15mg
    • Mansoura, Dakahlia, Egypt
      Faculty of Medicine
    2021-05-11
    May 11, 2021
    U
    A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
    Recruiting
    • Myeloproliferative Neoplasm
    • +2 more
    • Online Mindfulness Meditation
    • Internet-Based Webinars
    • San Francisco, California
      University of California San Francisco
    2022-02-22
    Feb 22, 2022
    U
    Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
    Active, not recruiting
    • CML, Chronic Phase
    • +4 more
    • Chapel Hill, North Carolina
      UNC Hospital
    2021-08-27
    Aug 27, 2021
    I
    Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response - 2017
    Terminated
    Has Results
    • Leukemia, Myeloid, Chronic-Phase
    • Imatinib Mesylate 600 MG Oral Tablet
    • +2 more
    • Bordeaux, Aquitaine, France
      Institut Bergonié
    2020-12-30
    Dec 30, 2020
    T
    Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Recruiting
    • CML, Chronic Phase; TKI
    • Flumatinib Mesylate
    • Nilotinib Pill
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University, Jiangsu Ins
    2021-02-01
    Feb 1, 2021
    M
    Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    2022-01-19
    Jan 19, 2022
    M
    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    2022-01-20
    Jan 20, 2022
    M
    Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia
    • Milwaukee, Wisconsin
      Froedtert Hospital & the Medical College of Wisconsin
    2021-11-10
    Nov 10, 2021
    H
    Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients - 2019
    Completed
    • Chronic Phase Chronic Myeloid Leukemia
    • Tampa, Florida
      H. Lee Moffitt Cancer Center and Research Institute
    2021-01-04
    Jan 4, 2021
    M
    ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    2021-12-29
    Dec 29, 2021
    F
    Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
    Recruiting
    • Chronic Phase-Chronic Myeloid Leukemia
    • Bosutinib 400 MG Monotherapy
    • Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
    • Madrid, Spain
      Hospital Universitario Ramón y Cajal
    2021-03-08
    Mar 8, 2021
    W
    Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
    Recruiting
    • CML-CP; Mutation;Suboptimal Response or Failure in TKI
    • Wuhan, Hubei, China
      Weiming Li
    2021-05-31
    May 31, 2021
    M
    Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
    Active, not recruiting
    • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    2021-05-05
    May 5, 2021
    G
    Study in Patients With Chronic Leukemia, Where Previous Therapy Failed, and Who Will be Treated With Ponatinib as Second Line Therapy
    Recruiting
    • Leukemia, Myeloid, Chronic-Phase
    • Halle (Saale), Saxony-Anhalt, Germany
    • +9 more
    2021-09-15
    Sep 15, 2021
    D
    Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia - 2020
    Completed
    • Leukemia
    • GM-K562 cell vaccine
    • imatinib mesylate
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    2020-10-26
    Oct 26, 2020
    U
    Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia - 2018
    Completed
    • Chronic Phase Chronic Myeloid Leukemia
    • +4 more
    • Toronto, Ontario, Canada
      Princess Margaret Hospital / University Health Network
    2020-10-29
    Oct 29, 2020
    U
    A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
    Withdrawn
    • Leukemia, Chronic Myeloid
    • Ann Arbor, Michigan
    • +1 more
    2021-02-11
    Feb 11, 2021
    U
    Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
    Recruiting
    • Hematologic Diseases
    • +11 more
    • Ann Arbor, Michigan
      University of Michigan Health System
    2021-12-02
    Dec 2, 2021
    N
    Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells - 2021
    Completed
    • Leukemia, Myeloid, Chronic-Phase
    • Nilotinib 300mg BID
    • Gallarate, Milano, Italy
    • +16 more
    2021-01-11
    Jan 11, 2021